LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I.
Acromegaly is associated with changes in lipoprotein metabolism and an excess in cardiovascular mortality. We have examined low density lipoprotein (LDL) subfraction distribution in 24 patients with active acromegaly and in controls matched for age, sex and body mass index. LDL was subfractionated by density gradient ultracentrifugation. The concentration of small dense LDL-III was significantly higher in the acromegalic patients compared to the controls (94.2 +/- 44.9 versus 67.2 +/- 30.4 mg/dl, P < 0.05) and there was a concomitant reduction in the intermediate subfraction LDL-II (124.8 +/- 31.3 versus 149.9 +/- 30.0 mg/dl, P < 0.05). Univariate analysis showed that both growth hormone (GH) and insulin-like growth factor (IGF)-I correlated with LDL-III and inversely with LDL-II. Acromegalic patients were found to have lower hepatic lipase (HL) and lipoprotein lipase (LPL) activities than controls (HL: 13.29 +/- 6.56 versus 21.58 +/- 7.27 micromol FFA released/ml/h, P < 0.001: LPL: 7.22 +/- 3.04 versus 11.53 +/- 7.85 micromol FFA released/ml/h, P < 0.05) whereas plasma cholesteryl ester transfer protein (CETP) activity was significantly increased (8.15 +/- 1.81 versus 5.54 +/- 1.86 pmol/microl/h, P < 0.001). Both GH and IGF-I were significantly associated with HL, LPL and CETP activities. Multivariate analysis on this relatively small sample size showed that in normal subjects, triglyceride and HL activity were the major determinants of LDL-III. In contrast, GH and HDL were the main determinants in acromegaly, accounting for 32 and 24% in the variability of LDL-III respectively. In conclusion, GH excess has a direct effect on LDL subfraction distribution.
Tan
K C
KC
Department of Medicine, University of Hong Kong.
Shiu
S W
SW
Janus
E D
ED
Lam
K S
KS
D000172:Acromegaly / Q000097:blood* / Q000188:drug therapy; D001053:Apolipoproteins / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D001971:Bromocriptine / Q000627:therapeutic use; D002352:Carrier Proteins / Q000097:blood; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006023:Glycoproteins; D013006:Growth Hormone / Q000097:blood* / Q000187:drug effects; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000378:metabolism*; D008049:Lipase / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood* / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D015415:Biomarkers; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D005230:Fatty Acids, Nonesterified; D006023:Glycoproteins; D006727:Hormone Antagonists; D008077:Lipoproteins, LDL; D014280:Triglycerides; D001971:Bromocriptine; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D008049:Lipase; D008071:Lipoprotein Lipase